Vaccinex, Inc. (NASDAQ:VCNX) Short Interest Update

Vaccinex, Inc. (NASDAQ:VCNXGet Free Report) was the recipient of a significant decline in short interest in March. As of March 31st, there was short interest totalling 6,300 shares, a decline of 28.4% from the March 15th total of 8,800 shares. Currently, 1.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 12,000 shares, the short-interest ratio is currently 0.5 days.

Institutional Trading of Vaccinex

Institutional investors have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP lifted its holdings in shares of Vaccinex by 250.2% in the first quarter. Susquehanna International Group LLP now owns 99,105 shares of the company’s stock valued at $40,000 after purchasing an additional 70,805 shares in the last quarter. Citadel Advisors LLC lifted its holdings in shares of Vaccinex by 92.1% in the third quarter. Citadel Advisors LLC now owns 100,268 shares of the company’s stock valued at $50,000 after purchasing an additional 48,064 shares in the last quarter. Worth Venture Partners LLC purchased a new stake in shares of Vaccinex in the first quarter valued at about $88,000. Millennium Management LLC lifted its holdings in shares of Vaccinex by 391.2% in the second quarter. Millennium Management LLC now owns 151,666 shares of the company’s stock valued at $164,000 after purchasing an additional 120,787 shares in the last quarter. Finally, Armistice Capital LLC purchased a new stake in shares of Vaccinex in the third quarter valued at about $768,000. Hedge funds and other institutional investors own 50.11% of the company’s stock.

Vaccinex Price Performance

VCNX stock opened at $6.13 on Friday. Vaccinex has a 52 week low of $5.87 and a 52 week high of $100.80. The company’s 50-day moving average price is $8.32 and its 200 day moving average price is $10.22.

Vaccinex Company Profile

(Get Free Report)

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.

Featured Stories

Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.